PharmaCyte Biotech Statistics
Total Valuation
PMCB has a market cap or net worth of $13.36 million. The enterprise value is -$13.94 million.
| Market Cap | 13.36M |
| Enterprise Value | -13.94M |
Important Dates
The next estimated earnings date is Friday, December 13, 2024, after market close.
| Earnings Date | Dec 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PMCB has 7.68 million shares outstanding. The number of shares has decreased by -51.83% in one year.
| Shares Outstanding | 7.68M |
| Shares Change (YoY) | -51.83% |
| Shares Change (QoQ) | -5.79% |
| Owned by Insiders (%) | 2.60% |
| Owned by Institutions (%) | 15.97% |
| Float | 7.29M |
Valuation Ratios
The trailing PE ratio is 3.25.
| PE Ratio | 3.25 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.40
| Current Ratio | 4.40 |
| Quick Ratio | 4.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 47.88% and return on invested capital (ROIC) is -6.35%.
| Return on Equity (ROE) | 47.88% |
| Return on Assets (ROA) | -4.76% |
| Return on Capital (ROIC) | -6.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $2.25M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.97% in the last 52 weeks. The beta is -0.20, so PMCB's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | -21.97% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 45.97 |
| Average Volume (20 Days) | 55,338 |
Short Selling Information
The latest short interest is 21,052, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 21,052 |
| Short Previous Month | 18,586 |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.63 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.71M |
| Pretax Income | -1.14M |
| Net Income | 4.50M |
| EBITDA | n/a |
| EBIT | -5.71M |
| Earnings Per Share (EPS) | $0.54 |
Balance Sheet
| Cash & Cash Equivalents | 32.64M |
| Total Debt | n/a |
| Net Cash | 32.64M |
| Net Cash Per Share | $4.25 |
| Equity (Book Value) | 53.04M |
| Book Value Per Share | 6.18 |
| Working Capital | 25.40M |
Cash Flow
| Operating Cash Flow | -2.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.87M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PMCB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 51.83% |
| Shareholder Yield | 51.83% |
| Earnings Yield | 33.64% |
| FCF Yield | -21.46% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 12, 2021. It was a reverse split with a ratio of 0.0006667:1.
| Last Split Date | Jul 12, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.0006667:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |